Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Xiangxue Approved to Start China Trial of T-Cell Therapy for Solid Tumors

publication date: Mar 21, 2019

Guangzhou Xiangxue Life Sciences (XLifeSc), a subsidiary of Xiangxue Pharmaceutical, was approved by China's NMPA to start clinical studies of its T-cell receptor Affinity Enhanced Specific T-cell (TAEST) therapy in patients with solid tumors. Earlier, XLifeSc announced positive results from a small pilot study of the TAEST thrapy in China. Xiangxue in-licensed the therapy from Athenex, a New York state biopharma. The two companies jointly formed Axis Therapeutics, which owns global rights (ex-China) to the TAEST therapy. More details....

Stock Symbols: (SHA: 300147) (NSDQ: ATNX)

Share this with colleagues:



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here